Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion

Graefe s Archive for Clinical and Experimental Ophthalmology(2021)10.1007/s00417-021-05494-5Source: DataRank Database

SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion is a research paper published in Graefe s Archive for Clinical and Experimental Ophthalmology (2021). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 0.90)OA: greenTopics (46)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (4)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Neal L. Oden ORCID,Paul VanVeldhuisen,Michael S. Ip ORCID,Barbara A. Blodi,for the SCORE2 Investigator Group

Live enrichment

PubMed:34842984 PMC:PMC10887424 OpenAlex:https://openalex.org/W3216127258

national eye institute

Grant: 1U10EY023533

national eye institute

Grant: 1U10EY023529

national eye institute

Grant: 1U10EY023521

NEI NIH HHS

Grant: U10 EY023533

NEI NIH HHS

Grant: U10 EY023521

NEI NIH HHS

Grant: UG1 EY023533

NEI NIH HHS

Grant: U10 EY023529

National Institutes of Health

Grant: 5U10EY023533-05

SCORE2 Comparative Trial (SCT)

National Institutes of Health

Grant: 4U10EY023529-03

SCORE2 Comparative Trial (SCT)

National Institutes of Health

Grant: 5U10EY023521-02

SCORE2 Comparative Trial (SCT)

research to prevent blindness

FWCI

0.90

Citation Percentile

0.7%

Citation Trend

2023

2024

2025

greenLicense: Springer TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10887424/pdf/nihms-1788988.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00417-021-05494-5.pdf

publisherhttps://link.springer.com/article/10.1007/s00417-021-05494-5/fulltext.html

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10887424

Fields of Study

Retinal Diseases and TreatmentsRetinal and Macular SurgeryOcular Diseases and Behçet’s Syndrome03 medical and health sciences0302 clinical medicineAngiogenesis InhibitorsBevacizumabHumansIntravitreal InjectionsMacular EdemaRetinal Vein OcclusionTomography, Optical CoherenceTreatment OutcomeValsartanVascular Endothelial Growth Factors

MeSH Terms

BevacizumabValsartanHumansMacular EdemaRetinal Vein OcclusionTreatment OutcomeAngiogenesis InhibitorsTomography, Optical CoherenceVascular Endothelial Growth FactorsIntravitreal Injections

Keywords

Central retinal vein occlusionOcclusionMedicineVEGF receptorsOphthalmologyVeinInternal medicineMacular edemaVisual acuityAnti-vegf TreatmentHemiretinal Vein OcclusionMacular Thickness FluctuationVascular Endothelial Growth FactorsAngiogenesis InhibitorsBevacizumabTreatment OutcomeIntravitreal InjectionsRetinal Vein OcclusionHumansValsartanTomography, Optical Coherence

Sustainable Development Goals

SDG 2: 2. Zero hungerSDG 3: 3. Good healthSDG 16: 16. Peace & justiceSDG 0: Zero hunger